
Bioequivalent to the brand product Norvasc® Produced by Cipla Ltd, a leading provider of generic pharmaceuticals.

Norvasc® is a trademark of Pfizer.



Quality That Is World Class



Cipla - Your Healthcare Partner Since 1935

Key Facts about Cipla Ltd.

25 manufacturing facilities approved by leading regulatory authorities including the FDA (USA), MHRA (UK) and TGA (Australia).

Over 1000 Formulations and 150 actives (APIs).

Supplier to the World Health Organisation (WHO).

The World's largest range of antiasthmatic aerosols and inhalation devices.

The World's largest manufacturer of antiretroviral drugs and supplier to the Clinton Foundation HIV/AIDS Initiative.


- GRADUAL ONSET OF ACTION ¹
- SMOOTH REDUCTION IN BP 1
- GENUINE ONCE-DAILY DOSING ²

- TROUGH/PEAK RATIO OF 67%
- WELL TOLERATED IN BOTH THE YOUNG AND THE ELDERLY 1
- CAN BE COMBINED WITH NITRATES, BETA-BLOCKERS, ACE INHIBITORS AND DIURETICS

24-hour Hypertension Control

CONSISTENT ANTIHYPERTENSIVE EFFECT THROUGHOUT 24 HOURS ²

- Minimal target organ damage due to lesser flucuations in blood pressure.²
- Better tolerability. 3



Hourly means of systolic and diastolic ambulatory blood pressure (+SD)

24-hour Angina Control

46% REDUCTION IN ANGIOPLASTY AND BYPASS SURGERY

The major importance of PREVENT is that amlodipine showed dramatic effect for reducing cardiovascular events, hospitalisations for angia, angioplasty and bypass surgery in patients with coronary disease. 4

REFERENCES:

- 1. Drugs 1995: 50:560-586
- 2. Eut J Clin Pharmacol 1993; 45:425-430
- 3. J. of Hypertension 1994; 12(8):573-576
- 4. Circulation 2000; 102:1503-1510

Distributed by

Controlled Medications Ltd. Unit 204, 2/F New Bright Building, 11 Sheung Yuet Road, Kowloon Bay, Kowloon, Hong Kong Tel: (852) 2896 0889 Fax: (852) 2898 9842

31% REDUCTION IN CARDIO-VASCULAR EVENTS

The PREVENT trial*, involving 825 patients with coronary artery disease, demontrated remarkable findings with amlodipine. ⁴

